Inequities in atherosclerotic cardiovascular disease prevention

被引:1
|
作者
Gomez, Sofia E. [1 ]
Dudum, Ramzi [1 ]
Rodriguez, Fatima [2 ]
机构
[1] Stanford Univ, Dept Med, Div Cardiovasc Med, Stanford, CA USA
[2] Stanford Univ, Ctr Acad Med, Div Cardiovasc Med, 453 Quarry Rd, Stanford, CA 94304 USA
关键词
Cardiovascular disease prevention; Inequity; Health disparities; NUTRITION EXAMINATION SURVEYS; AMERICAN HEART ASSOCIATIONS; CARDIAC REHABILITATION; NATIONAL-HEALTH; UNITED-STATES; SOCIAL DETERMINANTS; CLINICAL-TRIALS; SEX-DIFFERENCES; RISK-FACTORS; US ADULTS;
D O I
10.1016/j.pcad.2024.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerotic cardiovascular (CV) disease (ASCVD) prevention encompasses interventions across the lifecourse: from primordial to primary and secondary prevention. Primordial prevention begins in childhood and involves the promotion of ideal CV health (CVH) via optimizing physical activity, body mass index, blood glucose levels, total cholesterol levels, blood pressure, and sleep while minimizing tobacco use. Primary and secondary prevention of ASCVD thereafter centers around mitigating ASCVD risk factors via medical therapy and lifestyle interventions. Disparities in optimal preventive efforts exist among historically marginalized groups in each of these three prongs of ASCVD prevention. Children and adults with a high burden of social determinants of health also face inequity in preventive measures. Inadequate screening, risk factor management and prescription of preventive therapeutics permeate the care of certain groups, especially women, Black, and Hispanic individuals in the United States. Beyond this, individuals belonging to historically marginalized groups also are much more likely to experience other ASCVD risk -enhancing factors, placing them at higher risk for ASCVD over their lifetime. These disparities translate to worse outcomes, with higher rates of ASCVD and CV mortality among these groups. Possible solutions to promoting equity involve community -based youth lifestyle interventions, improved risk -factor screening, and increasing accessibility to healthcare resources and novel preventive diagnostics and therapeutics.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 50 条
  • [41] PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG SABENA FLYING PERSONNEL
    ANET, P
    BROUNS, H
    VANDENAB.KG
    DELESCLUSE, A
    MALCOLM, J
    AEROSPACE MEDICINE, 1972, 43 (10): : 1147 - +
  • [42] Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews
    Karmali, K. N.
    Loyd-Jones, D. M.
    Berendsen, M. A.
    JAMA CARDIOLOGY, 2017, 2 (04) : 461 - 461
  • [43] Risk scoring in primary prevention of atherosclerotic cardiovascular disease: Strengths and limitations
    De Backer, Guy G.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (14) : 1531 - 1533
  • [44] Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease Advances in Diagnosis and Treatment
    Mora, Samia
    Manson, JoAnn E.
    JAMA INTERNAL MEDICINE, 2016, 176 (08) : 1195 - 1204
  • [45] Impact of Lipid Lowering Therapies on the Primary Prevention of Atherosclerotic Cardiovascular Disease
    Akruti P. Prabhakar
    Deepak Vedamurthy
    Dinesh K. Kalra
    Current Cardiovascular Risk Reports, 2025, 19 (1)
  • [46] To Be or Not to Be: Elevated Troponin and the Role of Secondary Prevention of Atherosclerotic Cardiovascular Disease in ESKD
    Yip, Laverne
    Vohra, Ammar Arif
    Lim, Chee Yao
    Johan, Kenneth
    Soe, May Hnin Pwint
    Almanzar, Mirtha Camila
    Gutierrez, Jorge
    Patel, Pinal
    Ortega, Martinez Juan
    Menghrajani, Rajiv Hans Solita
    Park, Jiwon
    Chijioke, Chidinma Blossom
    Menon, Vidya
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [47] Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease
    Agarwal, Anubha
    Mehta, Priya M.
    Jacobson, Tyler
    Shah, Nilay S.
    Ye, Jiancheng
    Zhu, Jingjing
    Wafford, Q. Eileen
    Bahiru, Ehete
    de Cates, Angharad N.
    Ebrahim, Shah
    Prabhakaran, Dorairaj
    Rodgers, Anthony
    Huffman, Mark D.
    NATURE MEDICINE, 2024, 30 (04) : 1199 - 1209
  • [48] Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease The Aspirin Dilemma
    Mora, Samia
    Shufelt, Chrisandra L.
    Manson, JoAnn E.
    JAMA INTERNAL MEDICINE, 2022, 182 (06) : 587 - 589
  • [49] ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    不详
    ENDOCRINE PRACTICE, 2022, 28 (12)
  • [50] The International Task Force for Prevention of Coronary Heart Disease - Guidelines for prevention of atherosclerotic cardiovascular diseases
    Assmann, G
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 7 - 7